Eli Lilly faced competitive pressure after the Biogen CEO suggested that an at-home Alzheimer's treatment could provide a significant logistical advantage over Lilly’s currently favored infused therapy, Kisunla.
- Shares of Eli Lilly traded lower by 0.84%.
- The decline was exacerbated by a broader market reaction to hotter-than-expected inflation data.